Insmedの空売り状況は、投資家がInsmedの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Insmed (NASDAQ:INSM) 株価情報, 空売り情報

Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Insmed Inc

INSMED ORD

Truist Securities analyst Nicole Germino reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $100 to $105.

News

Price Target

Reiteration

Analyst Ratings

INSM

Truist Securities Reiterates Buy on Insmed, Raises Price Target to $105

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and maintains $90 price target.

HC Wainwright & Co. Reiterates Buy on Insmed, Maintains $90 Price Target

Biotech

Earnings

Guidance

Health Care

General

Insmed Reiterates Its Guidance For Full-year 2024 Global Arikayce Revenues Of $340M-$360M

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(1.21) by 4.96 percent. The company reported quarterly sales of $93.42 million which beat the analyst consensus estimate of $93.01 million by 0.44 percent. This is a 18.15 percent increase over sales of $79.07 million the same period last year.

Insmed Q3 2024 GAAP EPS $(1.27) Misses $(1.21) Estimate, Sales $93.42M Beat $93.01M Estimate

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) is gearing up to announce its quarterly earnings on Thursday, 2024-10-31. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Insmed will report an earnings per share (EPS) of $-1.21.
Investors in Insmed are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
Last quarter the company missed EPS by $0.67, which was followed by a 3.02% increase in the share price the next day.
Here's a look at Insmed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.27</td>
<td>-1.23</td>
<td>-1.15</td>
<td>-1.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.94</td>
<td>-1.06</td>
<td>-1.28</td>
<td>-1.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730297050_0.png" alt="eps graph" />
<a href="https://www.benzinga.com/quote/INSM/earnings">To track all earnings releases for Insmed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Insmed's Earnings Potential

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 6.11% on an annualized basis producing an average annual return of 17.42%. Currently, Insmed has a market capitalization of $12.29 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $4,953.54 today based on a price of $71.52 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729874375_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has risen 8.04% since its last report. The company recently reported that it has 13.20 million shares sold short, which is 7.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729786627_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 5.08%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Insmed's Recent Short Interest

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 6.97% on an annualized basis producing an average annual return of 18.54%. Currently, Insmed has a market capitalization of $12.83 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $552.22 today based on a price of $74.66 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729026018_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today

Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $85 to $100.

Truist Securities Maintains Buy on Insmed, Raises Price Target to $100

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $84 to $86.

B of A Securities Maintains Buy on Insmed, Raises Price Target to $86

—Data Presented at the CHEST 2024 Annual Meeting—
BRIDGEWATER, N.J., Oct. 8, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today presented positive late-breaking subgroup data from the Phase 3 ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. Posters with the details from these subgroup analyses can be found <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4272617-1&amp;h=1623866854&amp;u=https%3A%2F%2Finvestor.insmed.com%2Fevents%3Fitem%3D127&amp;a=HERE">HERE</a>. These data were presented at the CHEST 2024 Annual Meeting, held October 6-9 in Boston, along with several other presentations from across Insmed's respiratory portfolio.

Insmed Inc Presents New Subgroup Analyses From Landmark Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis Demonstrate Consistency With Overall Trial Population Results At The CHEST 2024 Annual Meeting

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $72 to $74.

JP Morgan Maintains Overweight on Insmed, Raises Price Target to $74

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.39% on an annualized basis producing an average annual return of 18.6%. Currently, Insmed has a market capitalization of $12.71 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $561.05 today based on a price of $73.95 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726851688_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years

Looking for broad exposure to the Small Cap Value segment of the US equity market? You should consider the JPMorgan BetaBuilders U.S. Small Cap Equity ETF (ARCA:BBSC), a passively managed exchange traded fund launched on 11/16/2020.
The fund is sponsored by J.P. Morgan. It has amassed assets over $520.35 million, making it one of the average sized ETFs attempting to match the Small Cap Value segment of the US equity market.
<h2>Why Small Cap Value</h2>
Small cap companies have market capitalization below $2 billion. They usually have higher potential than large and mid cap companies with stocks but higher risk.
While value stocks have lower than average price-to-earnings and price-to-book ratios, they also have lower than average sales and earnings growth rates. Value stocks have outperformed growth stocks in nearly all markets when you consider long-term performance, growth stocks are more likely to outpace value stocks in strong bull markets.
<h2>Costs</h2>
Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF&#39;s expense ratio.
Annual operating expenses for this ETF are 0.09%, making it one of the least expensive products in the space.
It has a 12-month trailing dividend yield of 1.48%.
<h2>Sector Exposure and Top Holdings</h2>
Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund&#39;s holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation to the Financials sector--about 19.90% of the portfolio. Healthcare and Industrials round out the top three.
Looking at individual holdings, Jpmorgan Us Govt Mmkt Fun accounts for about 1.50% of total assets, followed by Insmed Inc Common Stock (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/insm#NASDAQ">INSM</a>) and Carpenter Technology (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/crs#NYSE">CRS</a>).
The top 10 holdings account for about 5.66% of total assets under management.
<h2>Performance and Risk</h2>
BBSC seeks to match the performance of the MORNINGSTAR US SML CP TRG MRK EXP EXT ID before fees and expenses. The Morningstar US Small Cap Target Market Exposure Extended Index is a free-float adjusted, market-cap weighted index that targets small cap securities traded in the U.S.
The ETF has gained about 7.42% so far this year and it&#39;s up approximately 20.46% in the last one year (as of 09/16/2024). In the past 52-week period, it has traded between $48.58 and $67.50.
The ETF has a beta of 1.08 and standard deviation of 23.45% for the trailing three-year period. With about 796 holdings, it effectively diversifies company-specific risk.
<h2>Alternatives</h2>
JPMorgan BetaBuilders U.S. Small Cap Equity ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, BBSC is an excellent option for investors seeking exposure to the Style Box - Small Cap Value segment of the market. There are other additional ETFs in the space that investors could consider as well.
The Avantis U.S. Small Cap Value ETF (ARCA:AVUV) and the Vanguard Small-Cap Value ETF (ARCA:VBR) track a similar index. While Avantis U.S. Small Cap Value ETF has $12.95 billion in assets, Vanguard Small-Cap Value ETF has $29.58 billion. AVUV has an expense ratio of 0.25% and VBR charges 0.07%.
<h2>Bottom-Line</h2>
Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.
<a href="https://www.zacks.com/stock/news/2336240/should-jpmorgan-betabuilders-u-s-small-cap-equity-etf-bbsc-be-on-your-investing-radar?cid=CS-BENZ-FT-style_box_etf-2336240">To read this article on Zacks.com click here.</a>

Large Cap

Mid Cap

Sector ETFs

Dividends

Small Cap

Markets

ETFs

AVUV

BBSC

Should JPMorgan BetaBuilders U.S. Small Cap Equity ETF Be on Your Investing Radar?

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has fallen 9.3% since its last report. The company recently reported that it has 12.23 million shares sold short, which is 7.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726502419_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 6.00%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(INSM) - Analyzing Insmed's Short Interest

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.82% on an annualized basis producing an average annual return of 18.36%. Currently, Insmed has a market capitalization of $12.29 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $5,347.05 today based on a price of $71.49 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725984016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cantor Fitzgerald analyst Josh Schimmer reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight.

Cantor Fitzgerald Reiterates Overweight on Insmed

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 7.94% on an annualized basis producing an average annual return of 18.82%. Currently, Insmed has a market capitalization of $13.31 billion. 
Buying $1000 In INSM: If an investor had bought $1000 of INSM stock 10 years ago, it would be worth $5,609.70 today based on a price of $77.45 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724680820_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today

Watching Shares Of Insmed; Traders Circulating Mentions Of Company In Popular M&A Blog

Baron Health Care Fund Q3 2024 Shareholder Letter

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (INSM – Research Report), GlaxoSmithKline (GSK – Research ...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)

Here's the major earnings before the open tomorrow

Insmed GAAP EPS of -$1.27 misses by $0.06, revenue of $93.43M beats by $0.26M

Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript

Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Insmed (INSM – Research Report). The associated price target remains the same wi...

Insmed's Strong Revenue Growth and Promising Pipeline Drive Buy Rating

In a report released today, Leon Wang from Barclays maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $90.00. The ...

Barclays Sticks to Its Buy Rating for Insmed (INSM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY – Research Report) and Insmed (INSM – Resear...

Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY) and Insmed (INSM)

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Insmed (INSM – Research Report), with a price target of $75.00...

Evercore ISI Reaffirms Their Buy Rating on Insmed (INSM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Haleon PLC Sponsored ADR (HLN – Research Report), Insmed (INSM – ...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)

ABEV

ACLX

AGIO

ALGM

ALNY

AMKBY

AMLX

APTV

ARGNF

ARGX

ATGFF

AVNT

BALL

BAND

BBVA

BCAP

BMYMP

BNPQF

BROE

CCRD

CIFR

CMCSA

CMPS

CPSH

DFIN

DINO

DXCM

FLWS

FNMA

GLPG

GNRC

GPRE

ICLR

IDCC

IDXX

IRTC

ISNPY

ISRG

ITRI

PCVX

RARE

RDNT

REGN

VRTX

Press Releases

Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update

New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results

Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024

Insmed Unites Across Communities Around the World During Third Annual Global Day of Good

Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update

Comments

Insmed

空売り

Insmed (NASDAQ:INSM) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル